Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

Rhea-AI Summary

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) released promising results from an in-vivo study on its drug candidate RCC-33, showing a 35% increase in survival rate in mice with human colorectal cancer compared to controls. The experimental group had a mean survival of 31 days versus 23 days in the control group. The company plans to request a pre-IND meeting with the FDA next quarter and aims to initiate Phase 1/2a trials in early 2022. These findings support RCC-33's potential as a treatment option in a market estimated at $10 billion.

Positive

• 35% increase in survival rate observed in RCC-33 treated mice.
• Mean survival of 31 days in treatment group compared to 23 days in control.
• Plans to meet with the FDA and initiate clinical trials in early 2022.
• Potential market opportunity estimated at $10 billion.

Negative

• P-value of 0.08 indicates results may lack statistical significance.
• No concrete financial metrics or timelines for commercialization provided.

TEL AVIV, Israel and BETHESDA, Md., March 17, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice inoculated with human colorectal cancer cells. Study results indicate a 35% prolonged survival rate in mice exposed to RCC-33 in comparison with sham control mice, as shown by Kaplan-Meier survival curve analysis, P-value = 0.08 (Figure 1).

The mean survival rate observed in the experimental group was 31 days from treatment initiation vs. 23 days in the control group, reflecting a 35% increase in survival rate in the treatment group. The current results, taken together with previously obtained results of 33% reduction in tumor volume in the RCC-33 exposed group, further support the promising potential role of RCC-33 as part of the treatment armamentarium against colorectal cancer in the future. Company is aiming to schedule a pre-IND meeting with the US Food and Drug Administration by next quarter and start Phase 1/2a trials by beginning of 2022.

"Cannabics™ RCC-33 is the first proprietary antitumor formulation we have released for in-vivo testing. This, out of a developing pipeline of additional antitumor drug candidates that we are currently working on," said Eyal Barad, Cannabics Pharmaceuticals' Co-founder and CEO.  "Our aim with RCC-33 is to help a large and growing group of patients and assist in fulfilling a significant unmet need in an estimated $10 billion market."

Gabriel Yariv, Cannabics Pharmaceuticals' President and COO said, "Colorectal cancer accounts for 10% of all cancer cases worldwide, with an approximated 1.8M new cases diagnosed annually. CRC is also the second most lethal cancer type accounting for over 550k deaths annually. It is also estimated that over 65% of CRC patients will have a survival rate of 5 years or longer, which creates ample opportunity for RCC-33 to potentially become a part of their treatment regime."

About Cannabics Pharmaceuticals:

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company's R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as "believes," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company's management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed January 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source.

For more information about Cannabics:
Cannabics Pharmaceuticals Inc.
Phone: +1-(877)-424-2429
info@Cannabics.com
http://www.Cannabics.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/cannabics-pharmaceuticals-drug-candidate-rcc-33-prolongs-survival-rate-in-mice-inoculated-with-human-colorectal-cancer-cells-301249410.html

SOURCE Cannabics Pharmaceuticals Inc.

FAQ

What were the results of the Cannabics Pharmaceuticals RCC-33 study?

The study showed a 35% increase in survival rate in mice with human colorectal cancer treated with RCC-33.

When does Cannabics Pharmaceuticals plan to start clinical trials for RCC-33?

Cannabics Pharmaceuticals aims to initiate Phase 1/2a trials at the beginning of 2022.

What is the significance of the 35% survival increase in the RCC-33 study?

The 35% increase in survival rate suggests RCC-33 could be an effective treatment for colorectal cancer.

What market opportunity does Cannabics Pharmaceuticals see for RCC-33?

Cannabics Pharmaceuticals estimates a market opportunity of approximately $10 billion for RCC-33.

What is the next step for Cannabics Pharmaceuticals regarding RCC-33?

The company plans to schedule a pre-IND meeting with the FDA next quarter.